Prosthetic Heart Valve Market Report Scope & Overview:

The Prosthetic Heart Valve Market was valued at USD 10.30 Billion in 2025 and is expected to reach USD 29.73 Billion by 2035, growing at a CAGR of 11.18% from 2026-2035.

The Prosthetic Heart Valve market can be attributed to an increase in the prevalence of valvular heart disease cases in the world, including aortic stenosis and mitral regurgitation, and the aging population suffering from degenerative and calcific valve conditions. The move from the open surgery procedure to catheter-based procedures for valve replacement, which are associated with reduced risk and fast recovery, is another factor promoting the development of the market. Improvements in valve durability, advancements in the accuracy of delivery systems, and development of anti-calcification tissue platforms, among others, are the improvements being developed by manufacturers.

In September 2024, Edwards Lifesciences acquired JenaValve Technology and Endotronix for approximately USD 1.2 billion, strengthening its transcatheter valve and remote hemodynamic monitoring capabilities. The deals reflect a broader shift toward integrated structural heart solutions, combining device technologies with diagnostics and monitoring to support patient management and expand manufacturers’ competitive capabilities.

Prosthetic Heart Valve Market Trends

• Continued shift from surgical aortic valve replacement toward transcatheter aortic valve replacement (TAVR) procedures.

• Expansion of transcatheter valve indications into mitral and tricuspid valve disease beyond the traditional aortic segment.

• Growing adoption of anti-calcification tissue platforms designed to extend bioprosthetic valve durability.

• Rising investment in AI-assisted, software-guided transcatheter valve implantation systems.

• Increasing use of ambulatory surgical centers for select low-risk transcatheter valve procedures.

• Expansion of valve manufacturer footprints into Asia Pacific through local manufacturing and distribution partnerships.

U.S. Prosthetic Heart Valve Market Outlook

The U.S. Prosthetic Heart Valve Market was valued at USD 3.94 Billion in 2025 and is expected to reach USD 10.23 Billion by 2035, growing at a CAGR of 10.01% from 2026-2035.

The U.S. Prosthetic Heart Valves Market is continuing to benefit from the presence of established transcatheter valve reimbursement mechanisms, a widespread structural heart center network, and a good knowledge level among both patients and practitioners about the availability of minimally invasive valve replacement solutions. As transcatheter interventions are becoming more prevalent, developments in terms of valve technology, imaging, and intervention are opening up treatment to a larger variety of patients. The medical device companies are active in terms of clinical trials, regulatory activities, manufacturing, and commercialization in the U.S. and continue developing new products and driving the market forward.

In March 2024, Medtronic’s Evolut FX+ transcatheter aortic valve replacement system received FDA approval for symptomatic severe aortic stenosis. Its refined diamond-shaped frame is designed to improve coronary access while maintaining established hemodynamic performance, supporting continued device upgrades and replacement demand across high-volume U.S. structural heart programs.

Prosthetic Heart Valve Market Segment Analysis

• By Valve, the Transcatheter Heart Valves segment dominated the Prosthetic Heart Valve Market with approximately 47.50% share in 2025, while the Bioprosthetic (Tissue) Valves segment is the fastest growing with a CAGR of approximately 13.20%.

• By Material, the Biological Tissue segment dominated the Prosthetic Heart Valve Market with approximately 34.70% share in 2025, while the Pyrolytic Carbon segment is the fastest growing with a CAGR of approximately 12.80%.

• By End Use, the Hospitals segment dominated the Prosthetic Heart Valve Market with approximately 42.10% share in 2025, while the Ambulatory Surgical Centers segment is the fastest growing with a CAGR of approximately 13.50%.

By Valve, Transcatheter Heart Valves dominates, and Bioprosthetic (Tissue) Valves grows fastest

Transcatheter heart valves lead the Prosthetic Heart Valve Market in 2025, a position built on their ability to treat symptomatic severe aortic stenosis without the physiological burden of open-heart surgery, extending eligibility to elderly and high-surgical-risk patients previously managed conservatively. Continued clinical validation of transcatheter aortic valve replacement across low, intermediate, and high-risk patient categories has steadily widened the addressable procedural population, while expanding delivery-system refinements have improved coronary access and reduced paravalvular leakage, reinforcing physician confidence in the technology across an increasingly broad range of anatomies.

Bioprosthetic tissue valves are expanding fastest, supported by rising preference among younger and intermediate-risk patients seeking to avoid the lifelong anticoagulation therapy required with mechanical valves. Advances in anti-calcification tissue treatment platforms are extending the durability of bioprosthetic valves, narrowing a historical disadvantage relative to mechanical designs and broadening their clinical suitability. Growing use of tissue valves in patients with degenerative valve disease and infective endocarditis, combined with rising demand for transcatheter tissue valve platforms that combine minimally invasive delivery with anticoagulation-free management, continues to support the segment's above-average growth rate.

By Material, Biological Tissue dominates, and Pyrolytic Carbon grows fastest

Biological tissue-based prostheses, including valves made from the pericardium of cows and pigs, lead the Prosthetic Heart Valve Market in 2025. The wide use of such materials characterizes surgical and transcatheter bioprosthesis heart valves. This trend is explained by the preference of clinicians to biological tissue because of good hemodynamics and lack of necessity to use anticoagulants throughout a person’s whole life. Such a requirement became increasingly important in recent years with the increasing number of valve replacement surgery patients being younger people who want to live their lives with a high quality and without the use of anticoagulants.

Pyrolytic carbon is the fastest-growing material type due to its widespread application in mechanical heart valve leaflets and sewing rings. Good biocompatibility, high durability, and low risk of thromboembolism explain why it is used in durable mechanical heart valves. Clinical data proving that the lifespan of pyrolytic carbon-based mechanical heart valves is more than twenty years support the decision of doctors to implant them in young people, whereas manufacturers are improving bileaflet design that improves hemodynamics and thromboembolic protection compared with older generations of mechanical valves.

By End Use, Hospitals dominate, and Ambulatory Surgical Centers grow fastest

Hospitals represent the largest end-use category for prosthetic heart valves market in 2025, reflecting their role as the primary setting for both surgical and transcatheter valve replacement procedures that require advanced infrastructure, including catheterization labs, hybrid operating rooms, and multidisciplinary cardiac teams capable of managing high-risk and elderly patients. Hospitals maintain the comprehensive post-operative and emergency-care capabilities necessary for complex structural heart interventions, positioning them as the default site of care for the substantial majority of valve replacement volume.

Ambulatory surgical centers are growing fastest, as a subset of low-risk transcatheter aortic valve replacement procedures increasingly migrates toward outpatient settings equipped with advanced imaging and catheterization technology. Rising Medicare fee-for-service volumes processed through ASCs, combined with policy incentives favoring outpatient procedural sites, continue to support this shift for eligible patients. ASC operators are investing in the advanced imaging and catheterization infrastructure necessary to safely perform select transcatheter procedures, positioning this segment as an increasingly important complement to hospital-based structural heart programs.

Regional Analysis

North America Prosthetic Heart Valve Market Insights

North America accounted for approximately 45.00% of the Prosthetic Heart Valve Market in 2025, the largest share among all regions, supported by well-established healthcare infrastructure, substantial healthcare expenditure, and the concentrated presence of leading device manufacturers headquartered within the region. The United States drives the substantial majority of regional revenue, supported by supportive reimbursement frameworks for transcatheter procedures, efficient healthcare delivery systems, and a dense network of high-volume structural heart programs at academic and community hospitals alike. Canada contributes a smaller but stable share, concentrated in provincial hospital systems performing both surgical and transcatheter valve replacement.

Demand across the region continues to shift toward transcatheter platforms as clinical evidence extends TAVR eligibility across the full risk spectrum, from high-risk to low-risk patients. Leading manufacturers maintain their primary U.S. clinical trial and regulatory infrastructure, sustaining a steady cadence of new device approvals that reinforce North America's position as the first launch market for most next-generation valve technologies. Mexico represents a comparatively smaller but expanding market, as private hospital networks increase access to structural heart procedures for a growing population of aging patients.

Europe Prosthetic Heart Valve Market Insights

Europe represents the second largest regional market, led by Germany, the UK, and France. In these markets, national healthcare systems with CE marking facilitate the quick adoption of transcatheter valve technology following FDA approval. A high density of structural heart treatment centers in Germany and early adoption of CE marked products drive a consistent growth of procedure volumes, while the NHS in the United Kingdom maintains access expansion to transcatheter aortic valve implantation in the context of its general structural heart care strategy. The majority of reimbursement policies in Western European countries include valve and procedure cost into their national healthcare budgets, thus driving broad formulary access for certain manufacturers.

In France, where there is a high prevalence of heart valve diseases, and the government stimulates innovations in cardiology, the adoption of transcatheter heart valves, particularly TAVR, is fueled by high efficacy and economic efficiency in comparison to open surgery procedures. In Southern and Eastern Europe, represented by Italy and Spain, the capacity of structural heart programs increases due to the national healthcare programs to update the structure of cardiac catheterization labs. Regional distributors and national tender procedures continue to be important factors of access for some manufacturers into smaller public healthcare markets of Southern and Eastern Europe.

Asia Pacific Prosthetic Heart Valve Market Insights

Asia Pacific is the fastest-growing region in the Prosthetic Heart Valve Market, projected to expand at a CAGR of approximately 14.50% from 2026 to 2035, driven by a rapidly aging population, expanding structural heart program infrastructure, and rising government healthcare investment across China, Japan, and India. The region is home to nearly 60% of the world's population aged 60 and above, a demographic base that is directly accelerating demand for age-related valve replacement procedures. China represents the largest individual country market within the region, supported by an expanding network of structural heart centers and the emergence of domestic transcatheter valve manufacturers gaining regulatory approval both at home and increasingly abroad.

Japan and South Korea contribute stable, technology-forward demand, supported by well-established reimbursement pathways and strategic distribution partnerships that bring internationally developed valve platforms to market. India is emerging as a significant growth driver as government-backed initiatives, including dedicated centers of excellence for minimally invasive cardiovascular devices, expand treatment access for high-risk cardiac patients while fostering collaboration between domestic researchers and the local medical device industry. Manufacturers are responding with expanded regional manufacturing, training infrastructure, and distribution partnerships tailored to the regulatory and clinical preferences of individual Asia Pacific markets.

MEA & Latin America Prosthetic Heart Valve Market Insights

The Middle East and Africa region comprises of a smaller but important segment of the Prosthetic Heart Valve Market. The Middle East and North African countries are dominated by GCC nations such as Saudi Arabia and the United Arab Emirates. Investment in specialized cardiac centers of excellence coupled with the rise in government funding for structural heart programs have made transcatheter valve technologies gain acceptance in this region. Transcatheter aortic valve implantation has gained widespread use due to high volume centers which includes designated centers of excellence for adult cardiac surgery. South Africa leads the demand for Prosthetic Heart Valves across the whole of Africa continent owing to its relatively advanced private cardiac care sector despite infrastructural challenges of access outside the urban areas.

Latin America represents a steadily growing market for the Prosthetic Heart Valves due to high prevalence of cardiovascular diseases and initiatives taken by prominent companies to introduce next generation transcatheter valve platforms in the region. Brazil constitutes the largest market in Latin America with the growth fueled by the increase in aging population and transition towards minimally invasive surgeries despite the presence of regional disparities in health care facilities and expensive cost of heart valve treatment.

Market Dynamics

Growth Drivers: Rising Valvular Heart Disease Prevalence and Transcatheter Adoption

Growth in the Prosthetic Heart Valve Market is primarily attributed to the rising global prevalence of valvular heart disease, including rheumatic heart disease, calcific aortic valve disease, and degenerative mitral valve disease, conditions that collectively affect tens of millions of people worldwide and are among the leading causes of structural valve deterioration requiring surgical or transcatheter replacement. The expanding elderly population is a central driver of this trend, since degenerative and calcific valve disorders become substantially more common with advancing age, directly increasing the pool of patients eligible for valve replacement therapy.

The continued clinical validation and expanding indications for transcatheter valve replacement, including growing evidence supporting early intervention in asymptomatic severe aortic stenosis, are reinforcing physician and patient preference for minimally invasive approaches over traditional open-heart surgery. Government funding and awareness campaigns targeting heart valve disease education, including national initiatives supported by cardiovascular health legislation in several markets, are improving diagnosis rates and treatment-seeking behavior. Continued technological refinement in valve durability, delivery-system precision, and anti-calcification tissue platforms is further supporting sustained replacement-cycle and first-time procedural demand.

Restraints: High Procedural Costs and Stringent Regulatory Requirements

The expensive cost of heart valve replacement device products together with the cost of the procedures involved plays an important role in inhibiting the market from developing further. This is because in countries with highly price-sensitive markets, the cost of the device itself and the procedure becomes a factor when deciding whether or not the patient can afford the procedure. Strict regulations enforced by bodies such as the U.S. FDA, the European Medicines Agency, and the Japanese PMDA increase the time and cost that companies face during product development.

The lack of qualified interventional cardiologists and cardiac surgeons able to perform the procedure remains a challenge in many regions, and this problem is particularly acute outside major structural heart centers. Clinical concerns still exist related to the risks of infections, thromboembolism, and durability/structural valve deterioration associated with the heart valve replacement products. Such concerns may impact the decisions made by physicians as well as the patient themselves when choosing one type of valve over another or undergoing the procedure at all.

Opportunities: Expanding Transcatheter Indications and Emerging Market Access

Ongoing research and development expanding transcatheter valve applications beyond the aortic position into mitral and tricuspid valve disease presents a substantial opportunity for manufacturers to address patient populations that have historically lacked minimally invasive treatment options. Continued innovation in AI-assisted, software-guided implantation systems is creating an avenue for manufacturers to differentiate premium platforms and improve procedural precision, potentially supporting recurring software and service revenue streams alongside traditional device sales.

Entering emerging markets in the regions of Asia Pacific, Latin America, and the Middle East is another big area for business expansion. Companies are opening production facilities, training facilities, and distribution channels specifically to suit the regulatory and clinical requirements of the region. With an increasing prevalence of cardiovascular diseases in these regions, along with improved healthcare infrastructure, including government support in developing structural heart programs, there are significant opportunities for those who have entered the region first to benefit from first mover advantage.

Recent Developments:

• 2025 – Abbott’s Tendyne transcatheter mitral valve replacement system received FDA approval for severe mitral annular calcification patients at high surgical risk, expanding minimally invasive mitral treatment options.

• 2025 – Corcym received FDA clearance for its Lancelot valve, featuring collapsible bovine pericardium and a nitinol frame designed to simplify minimally invasive implantation procedures.

• 2024 – Boston Scientific’s ACURATE Prime Aortic Valve System received CE Mark approval for a new valve size, expanding treatment options for patients with larger anatomies.

• 2024 – MicroPort CardioFlow’s VitaFlow Liberty Transcatheter Aortic Valve received CE certification, becoming the first Chinese-developed TAVI device approved for European Union use.

• 2024 – Medtronic received FDA approval for its Avalus Ultra surgical aortic valve, featuring a low-profile design, radiopaque markers, and PEEK-based frame for improved valve-in-valve visibility.

Prosthetic Heart Valve Market Key Players

• Edwards Lifesciences Corporation

• Medtronic plc

• Abbott Laboratories

• Boston Scientific Corporation

• Artivion, Inc.

• MicroPort Scientific Corporation

• Lepu Medical Technology (Beijing) Co., Ltd.

• Venus Medtech (Hangzhou) Inc.

• Foldax, Inc.

• Meril Life Sciences

• TTK Healthcare Limited

• LivaNova PLC

• Corcym S.r.l.

• 4C Medical Technologies, Inc.

• Colibri Heart Valve, LLC

• Biotronik SE & Co. KG

• B. Braun Melsungen AG

• Sulzer AG

• Cardiovalve Ltd.

• JenaValve Technology, Inc.

Prosthetic Heart Valve Market Report Scope: